Filed by BioPlus Acquisition Corp. pursuant to
Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: BioPlus Acquisition Corp.
Commission File No.: 001-41116
Renown Cardiologist and Professor Ian T. Meredith, MD
to Join Avertix Medicals Board of Directors
Recently served as Boston Scientific Executive Vice President and Global Chief Medical Officer
Professor Meredith brings to Avertix over 35 years of cardiology experience and
commitment to advancing cardiac care
EATONTOWN, N.J., July 17, 2023 Avertix Medical, Inc. (Avertix or the Company), formerly known as
Angel Medical Systems, Inc., a healthcare technology company commercializing the first and only FDA-approved heart attack warning system to improve long-term management and outcomes of high-risk coronary
disease in patients, announced today that Professor Ian Meredith AM, has agreed to join the Companys Board of Directors following the closing of the Companys previously announced business combination with BIOS Acquisition
Corporation (dba BioPlus Acquisition Corp.) (BIOS) (Nasdaq: BIOS), a special purpose acquisition company. Professor Meredith recently retired from Boston Scientific after serving over six years as its Executive Vice President and Global
Chief Medical Officer, where he was responsible for global leadership of medical, clinical science and trial strategy across the organization. Prior to joining Boston Scientific, Professor Meredith served for 12 years as a professor and director of
MonashHeart, an internationally recognized cardiology service within Monash Healthand today serves as an Honorary Professor of Medicine and Cardiology at Monash University in Melbourne, Australia.
As an Avertix board member, Professor Meredith will bring his decades long experience as a leading interventional cardiologist and thought leadership to
Avertix.
We believe Professor Meredith is one of the worlds most eminent clinicians in both acute cardiac care and clinical
investigations, said Ross Haghighat, Executive Chairman of Avertix. As a highly respected and globally recognized interventional cardiologist, professor, and global medical executive of one of the most innovative cardiovascular product
companies in the world, we believe his expertise and insights will prove invaluable to Avertix. We are thrilled to have his guidance extend beyond the boardroom as we endeavor to advance both The Guardian System and our pipeline of future
innovations which we expect to shape a new era of cardiac monitoring for patients worldwide.
With more than 35 years of experience as a clinical
and interventional cardiologist, Professor Meredith has performed more than 20,000 invasive cardiac and coronary procedures, published more than 400 peer-reviewed manuscripts and book chapters, and has championed many new treatment paradigms into
daily clinical practice. He has been the chief or principal investigator on more than 50 major international multi-center trials, including several global first-in-human
studies.
Avertix has a meaningful product that holds the potential to empower patients at a time of great anxiety and uncertainty in their
lives, said Professor Meredith. I can say confidently after 35 years of caring for patients suffering a heart attack, with more than 20 of those as an interventional cardiologist undertaking primary percutaneous coronary intervention
(PCI) for their acute heart attack, that the fear of another cardiac event, and resulting death, is profound and often paralyzing to the point that many struggle to return to their normal daily activities, both personally and professionally. I
believe the aptly named Guardian offers a promising solution, providing individuals with renewed confidence and a sense of predictability albeit not absolute.